Duodenal ulcer
Drug research and approvals for duodenal ulcer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 30 studies of duodenal ulcer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 30
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- SPADE Clinical Trial.NCT07892183 · Not applicable · National Cancer Center, Korea · starts Jun 25, 2025
- PPI Dosing Per CYP2C19 GenotypeNCT07843264 · Phase 4 · University of Florida · starts Nov 1, 2026
- Preoperative Predictors of Symptom Improvement After Laparoscopic FundoplicationNCT07809620 · Not reported · Minia University · starts Sep 20, 2026
- A Prospective Cohort Study on Endoscopic Features of Upper Gastrointestinal Tract at High Altitude (Zaduo County)NCT07755384 · Not reported · Jilin University · starts Dec 1, 2025
- The Transit Bipartition With the Use of a Metallic Anastomosis Clip and Circular Fundocorporeal GastroplicationNCT07495020 · Not applicable · The Society of Bariatric and Metabolic Surgeons of Kazakhstan · starts Apr 30, 2026
- Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICUNCT07399054 · Not reported · Asian Institute of Gastroenterology, India · starts Feb 23, 2026
- Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'NCT07385235 · Phase 1 · Addpharma Inc. · starts Jan 27, 2026
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori…NCT07344506 · Phase 4 · Dow University of Health Sciences · starts May 1, 2025
- Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer…NCT07260006 · Not applicable · Can Tho University of Medicine and Pharmacy · starts Oct 1, 2024
Approved 15
- LansoprazolePotassium-transporting ATPase inhibitor
- RabeprazolePotassium-transporting ATPase inhibitor
- AmoxicillinBacterial penicillin-binding protein inhibitor
- OmeprazolePotassium-transporting ATPase inhibitor
- ClarithromycinBacterial 70S ribosome inhibitor
- MetronidazoleDNA inhibitor
- EsomeprazolePotassium-transporting ATPase inhibitor
- DiclofenacCyclooxygenase inhibitor
- MisoprostolProstanoid EP3 receptor agonist
- FamotidineHistamine H2 receptor antagonist
- CimetidineHistamine H2 receptor antagonist
- NizatidineHistamine H2 receptor antagonist
- RanitidineHistamine H2 receptor antagonist
- SucralfatePepsin A inhibitor
- TetracyclineBacterial 70S ribosome inhibitor
Phase 3 5
- VonoprazanPotassium-transporting ATPase inhibitor
- IlaprazolePotassium-transporting ATPase inhibitor
- Gefarnate
- Anaprazole
- TegoprazanPotassium-transporting ATPase blocker
Phase 2 4
- AspirinCyclooxygenase inhibitor
- NaproxenCyclooxygenase inhibitor
- CobiprostoneChloride channel protein 2 activator
- Teprenone
Phase 1 or earlier 1
- PantoprazolePotassium-transporting ATPase inhibitor
How its trials ended
70 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 21 whose ending is known, 86% met their primary endpoint, 0% missed it and 14% stopped early.
- Completed, result not reported3753%
- Met its primary endpoint1826%
- Status unknown913%
- Ongoing34%
- Stopped: enrollment or feasibility23%
- Stopped: lack of efficacy11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA